1h Free Analyst Time
The anti-thrombin III testing market is forecasted to grow by USD 87.8 million during 2023-2028, accelerating at a CAGR of 4.51% during the forecast period. The report on the anti-thrombin III testing market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by existence of tests related to anti-thrombin III, increase in number of people with hypertension, and shift toward rapid diagnostics.
The anti-thrombin III testing market is segmented as below:
By End-user
- Hospitals
- Laboratories
- Academic and research institutes
By Geographical Landscape
- North America
- Europe
- Asia
- Rest of World (ROW)
The report on the anti-thrombin III testing market covers the following areas:
- Anti-thrombin III testing market sizing
- Anti-thrombin III testing market forecast
- Anti-thrombin III testing market industry analysis
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.
Table of Contents
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by End-user
7 Customer Landscape
8 Geographic Landscape
9 Drivers, Challenges, and Opportunity/Restraints
10 Competitive Landscape
11 Competitive Analysis
12 Appendix
360 degree market analysis
List of Exhibits
Executive Summary
The following companies are recognized as the key players in the global anti-thrombin III testing market: Abbott Laboratories, Beckman Coulter Inc., Becton Dickinson and Co., Bio RAD Laboratories Inc., BIRON HEALTH GROUP, Danaher Corp., F. Hoffmann La Roche Ltd., Grifols SA, Invitae Corp., Merck KGaA, Meridian Bioscience Inc., Oy Medix Biochemica Ab, Randox Laboratories Ltd., Scripps Laboratories Inc., Sekisui Diagnostics LLC, Siemens AG, Sysmex Corp., Thermo Fisher Scientific Inc., Transasia Bio Medicals Ltd., and Werfenlife SA.Commenting on the report, an analyst from the research team said: "The latest trend gaining momentum in the market is presence of various blood clotting disorders."
According to the report, one of the major drivers for this market is the existence of tests related to anti-thrombin III.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Abbott Laboratories
- Beckman Coulter Inc.
- Becton Dickinson and Co.
- Bio Rad Laboratories Inc.
- BIRON HEALTH GROUP
- Danaher Corp.
- F. Hoffmann La Roche Ltd.
- Grifols SA
- Invitae Corp.
- Merck KGaA
- Meridian Bioscience Inc.
- Oy Medix Biochemica Ab
- Randox Laboratories Ltd.
- Scripps Laboratories Inc.
- Sekisui Diagnostics LLC
- Siemens AG
- Sysmex Corp.
- Thermo Fisher Scientific Inc.
- Transasia Bio Medicals Ltd.
- Werfenlife SA
